Partnering In – Business and Corporate Development
Open to new opportunities.
Merz Therapeutics has an ambitious growth strategy to become a leading player in neurology-focused specialty pharma. Partnerships are essential to our ambition, from biopharmas to promising specialty neuroscience innovators. We are poised for a period of transformational growth through new partnering and acquisition opportunities in addition to in-house R&D. Partner with us!
Transform Neuroscience With Us
An essential part of our growth strategy is partnership along the entire therapeutic lifecycle. Merz Therapeutics has a decisive business development strategy targeting specialty neuroscience development and commercial opportunities.
Our immediate focus is on Phase 2, Phase 3, and marketed opportunities. We also know it is never too early to lay the foundations for future collaborations. At Merz Therapeutics, we are also highly interested to discuss early-stage investments and to build relationships with pioneering innovators in specialty neurology.
Areas of priority disease focus include:
- Movement disorders and neurodegeneration, including Parkinson’s disease, multiple sclerosis, dystonia, spasticity, blepharospasms, ataxia and other diseases characterized by motor dysfunction
- Rare and orphan neurology disease including hereditary neuropathies and other neurodegenerative diseases, ideally with movement disorder aspects
- Chronic pain indications, including migraine and peripheral neuropathy
- Functional neurological disorders
Committed to Successful Collaboration
In every partnership, Merz Therapeutics is focused on cross-functional collaboration excellence with our partners. We believe partnerships require prioritized investment of people, time, and energy to thrive in today’s complex development and commercial environments. Merz Therapeutics is proud of our past partnership successes and our ongoing commitment to effective alliance management.
Meet Some of our Partners
Partnering Put into Practice
Examples of Merz Therapeutics’ success through partnership:
Acorda Therapeutics Asset Acquisition
In 2024, Merz Therapeutics wholly acquired two established and well-respected commercial medicines from Acorda Therapeutics, strengthening our market position in Parkinson’s disease and expanding into the multiple sclerosis segment. Post-acquisition, Merz Therapeutics further invested in global commercial infrastructure, patient access, global supply chain and international distribution to best deliver these products to patients globally.
Vensica Investment and Partnership
Since 2021, Merz Therapeutics is both an investor in Vensica, an early-stage technology company, and also a license partner of Merz’s incobotulinmumtoxinA for use with Vensica’s innovative ultrasound-assisted delivery catheter to treat overactive bladder. Merz Therapeutics is pleased to be more than an investor to Vensica, and to act as strategic, long-term partners with shared expertise.
Teijin Partnership
In 2017, Merz and Teijin entered a strategic license and co-development agreement for the Therapeutics commercialization of incobotulinmumtoxinA for Japan. By 2019, Japan’s Ministry of Health, Labor and Welfare (MHLW) granted approval to market incobotulinmumtoxinA in Japan for the treatment of upper limb spasticity, and in 2021 for lower limb spasticity.
Daiichi-Sankyo Partnership
In our longest running partnership, Merz Therapeutics licensed Merz’s memantine hydrochloride to Daiichi-Sankyo. In 2011, Daiichi-Sankyo announced the approval to market and manufacture memantine hydrochloride for the treatment of moderate to severe Alzheimer’s Disease in Japan.
Conferences
Merz Therapeutics will attend these conferences in the coming months and looks forward to connecting in person.
BIO International in Boston, June 16-19.
Introduce Yourself!
If you’re not sure whether it’s the right time to approach us, we assure you it is. We always look forward to meeting biopharmas and other product innovators.